Suggested remit: To evaluate the benefits and costs of olipudase alfa within its marketing
authorisation for treating Niemann-Pick disease types A and B for national
commissioning by NHS England.
|
Status
|
Awaiting development
|
|
Decision
|
None selected
|
| Process |
STA 2018
|
| ID number |
3913
|
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
19 January 2022 - 16 February 2022 |
| Scoping workshop |
17 March 2022 (10:00) |
Project Team
| Project lead |
Emily.richards@nice.org.uk |
Email enquiries
For further information on our processes and methods, please see our CHTE processes and methods manual